Abstract
Axonal loss is an important feature of Multiple Sclerosis (MS), being strongly related to irreversible disability accumulation. Nonetheless, the exact mechanisms underlying axonal loss remain unclear. Cerebrospinal fluid (CSF) levels of Tau and Beta-amyloid (Abeta) currently represent diagnostic biomarkers in other neurodegenerative diseases. In MS, studies on CSF Tau and Abeta provided preliminary informations on disease prognosis, but results have not yet been replicated.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 103231 |
Rivista | Multiple Sclerosis and Related Disorders |
Volume | 56 |
DOI | |
Stato di pubblicazione | Pubblicato - 2021 |
Keywords
- Amyloid beta-Peptides
- Axons
- Biomarker
- Biomarkers
- Humans
- Magnetic Resonance Imaging
- Multiple Sclerosis
- Multiple sclerosis
- Neurodegeneration
- Prognosis
- Tau
- tau Proteins